<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982032</url>
  </required_header>
  <id_info>
    <org_study_id>NL43116.041.13</org_study_id>
    <nct_id>NCT01982032</nct_id>
  </id_info>
  <brief_title>Edwards SAPIEN Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation (the ELECT Trial)</brief_title>
  <acronym>ELECT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve replacement (TAVR) is a good alternative treatment for patients
      with severe aortic valve stenosis with similar mid-term success rates as compared to
      surgery. Periprosthetic aortic regurgitation (PAR) after TAVR remains an important
      limitation of this technique. Moderate to severe PAR occurs in 15-45% of the cases and it is
      an independent predictor of mortality after TAVR. Little is known about potential
      differences in severity of PAR among different types of aortic valve prosthesis. The current
      randomized study aims to evaluate potential differences between the Edwards SAPIEN
      bioprosthesis and the Medtronic CoreValve® system with main focus on PAR and additional
      focus on other clinical and imaging endpoints. Primary objective of this study is to
      investigate the difference in the severity of PAR, measured with 3-dimensional
      transesophageal echocardiography (3DTEE), between patients undergoing the implantation of
      the Edwards SAPIEN bioprosthesis versus patients receiving the Medtronic CoreValve®
      bioprosthesis. Secondary objectives of this study include: investigating the value of
      different imaging modalities in evaluating periprosthetic regurgitation after TAVR and
      studying the difference in clinical endpoints according to VARC-2 definitions and quality of
      life after TAVR between two available aortic valve prostheses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PAR (expressed as regurgitant volume [ml]) after TAVR, as diagnosed with 3DTEE</measure>
    <time_frame>Within 5 days after TAVR</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PAR (expressed as regurgitant volume [ml]) after TAVR, as diagnosed with cardiac magnetic resonance imaging</measure>
    <time_frame>Within 5 days after TAVR</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAR (expressed as regurgitant volume [ml]) 6 months after TAVR, as diagnosed with 3DTEE</measure>
    <time_frame>At 6 months +/- 2 weeks after TAVR</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoints according to the VARC-2</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, presented as scores of the short form 36 item health status survey (SF-36) and the Euroqol questionnaire (EQ-5D)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Periprosthetic Aortic Valve Regurgitation After TAVR</condition>
  <arm_group>
    <arm_group_label>Edwards SAPIEN bioprosthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic CoreValve® system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter aortic valve replacement with the Medtronic CoreValve system</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement</intervention_name>
    <description>Transcatheter aortic valve replacement</description>
    <arm_group_label>Edwards SAPIEN bioprosthesis</arm_group_label>
    <arm_group_label>Medtronic CoreValve® system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve system</intervention_name>
    <description>Transcatheter aortic valve replacement with the Medtronic CoreValve system</description>
    <arm_group_label>Medtronic CoreValve® system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN bioprosthesis</intervention_name>
    <description>Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis</description>
    <arm_group_label>Edwards SAPIEN bioprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years of age or older and diagnosed with severe symptomatic aortic
             stenosis, judged inoperable or at high surgical risk (EuroSCORE &lt; 15%) and deemed
             eligible for TAVR by a consensus among a cardiologist and a cardiac surgeon
             (heart-team)

          -  Or a patient who is considered to be operable by the heart-team, but who chooses to
             undergo TAVI instead of conventional surgery

          -  Aortic annulus diameter ≥18 and ≤27 mm

          -  Patients who undergo TAVR via the transfemoral approach

        Exclusion Criteria:

          -  Patients with contraindications for TEE will be excluded

          -  Patients unable or unwilling to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierfrancesco Agostoni, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter Stella, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariam Samim, MD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierfrancesco Agostoni, MD, PhD</last_name>
    <phone>0031887556167</phone>
    <email>p.agostoni@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierfrancesco Agostoni, MD, PhD</last_name>
      <phone>0031887556167</phone>
      <email>p.agostoni@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Mariam Samim, MD</last_name>
      <phone>0031887559497</phone>
      <email>m.samim@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 30, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Pierfrancesco Agostoni</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Periprosthetic aortic valve regurgitation</keyword>
  <keyword>3D transesophageal echocardiography</keyword>
  <keyword>Cardiac MRI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
